The trademark application ZALABIV was filed by Amgen Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on September 8, 2015, and it was registered by office on December 16, 2015 without any oppositions.
The application was filed in Dutch (English was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations used for the treatment of parathyroid, glandular and hormone disorders
Pharmaceutical preparations used for the treatment of renal and kidney disorders.